top of page

Citius Pharmaceuticals, Inc. (CTXR) 


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Citius Pharmaceuticals, Inc. ("Citius" or "the Company") (NASDAQ: CTXR). The investigation concerns whether Citius and certain of its officers and/or directors have violated federal securities laws.


On July 1, 2021, Citius issued a press release entitled “Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok Phase 3 Trial as Planned.”  Although the press release framed its contents in positive terms, disclosing, among other things, that “following a unblinded data review of safety and efficacy, the independent Data Monitoring Committee (DMC) for the Mino-Lok® Phase 3 Pivotal Superiority Trial has recommended proceeding with the trial as planned” and “did not identify any safety concerns and no modifications were recommended to the protocol-defined sample size or power to achieve the primary endpoint”, analysts and industry observers noted that the trial’s third interim analysis scheduled for June 29, 2021 did not find evidence of superiority over standard care, contrary to investor expectations.  On this news, Citius’s stock price fell $0.88 per share, or 25.29%, to close at $2.60 per share on July 1, 2021.


If you are aware of any facts relating to this investigation, or purchased Citius shares, you can review a copy of the complaint and sign the certification form. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

bottom of page